Tectonic Therapeutic Inc TECX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $34.81
- Day Range
- $32.25–35.93
- 52-Week Range
- $14.40–38.81
- Bid/Ask
- $24.80 / $49.00
- Shares Outstanding
- 18.87M
- Market Cap
- $612.49M
- Volume/Avg
- 170,043 / 206,542
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.44%
Company Profile
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 60
- Website
- https://www.tectonictx.com
Valuation
|
Metric
|
TECX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.84 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TECX
|
|---|---|
Quick Ratio | 18.28 |
Current Ratio | 18.51 |
Interest Coverage | −1,828.22 |
Quick Ratio
TECX
Profitability
|
Metric
|
TECX
|
|---|---|
Return on Assets (Normalized) | −25.71% |
Return on Equity (Normalized) | −26.88% |
Return on Invested Capital (Normalized) | −30.72% |
Return on Assets
TECX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|XwndLJ | LOCK|<J%# | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?K!>cC% | LOCK|gVWl | $69B | |||
| argenx SE ADR
ARGX
| LOCK|#%&K$xc | LOCK|#pG | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|SK@wkG | LOCK|&>$^@ | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?!zTX<G | LOCK|pC# | $36B | |||
| Moderna Inc
MRNA
| LOCK|^pB!>@ | LOCK|fH | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kW!fBckT | LOCK|$&QMv | $25B | |||
| Incyte Corp
INCY
| LOCK|s&s&R$v | LOCK|K< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@gT&Xn | LOCK|d& | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Mr<qs%Z | LOCK|rF | $16B |
United States